23/07/2026
A major advancement in diabetes treatment is here. Once-weekly insulin (Insulin Icodec) is designed to stay active in the body for 7 days, reducing the number of insulin injections from 365 a year to just 52.
While this is a significant step forward, it may not be suitable for everyone. In patients with chronic kidney disease (CKD), blood sugar levels often fluctuate, so short-acting insulin continues to be the preferred option in many cases.
Research is also progressing on inhalational insulin, which has received FDA approval but is not yet commercially available, while oral insulin is still in the research phase.
Newer treatments are expanding options for diabetes care, but the right insulin always depends on an individual’s medical condition. Consult your doctor before making any changes to your treatment.